Poststroke hypertonicity: Upper limb assessment and treatment

Topics in Stroke Rehabilitation

Volumn 18, Issue 3, 2011, Pages 179-194

  Marciniak, Christina ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

assessment; botulinum toxin; hypertonicity; spasticity; stroke; upper limb

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CLONAZEPAM; DANTROLENE; DIAZEPAM; GABAPENTIN; PHENOL; TIZANIDINE;

ARM; ARM DISEASE; ARTICLE; CONFUSION; DISABILITY ASSESSMENT SCALE; DIZZINESS; DRUG EFFICACY; ELBOW FLEXION; FINGER; FLEXOR MUSCLE; FOREARM; FUGL MEYER SCALE; HUMAN; MEDICAL HISTORY; MODIFIED ASHWORTH SCALE; MODIFIED TARDIEU SCALE; MOTOR ASSESSMENT SCALE; MUSCLE CONTRACTURE; MUSCLE FUNCTION; MUSCLE HYPERTONIA; MUSCLE STRETCHING; MUSCLE TRAINING; MUSCLE WEAKNESS; NONHUMAN; PASSIVE MOVEMENT; PATIENT ASSESSMENT; QUALITY OF LIFE; RANGE OF MOTION; RATING SCALE; REST; RIVERMEAD MOTOR ASSESSMENT; SEDATION; SHOULDER; SIDE EFFECT; SOMNOLENCE; SPASM FREQUENCY SCALE; SPLINTING; STROKE; STROKE PATIENT; THUMB; VISUAL ANALOG SCALE;

ADULT; AGED, 80 AND OVER; BOTULINUM TOXINS; DISABILITY EVALUATION; HUMANS; MALE; MUSCLE HYPERTONIA; MUSCLE, SKELETAL; PAIN MEASUREMENT; PHYSICAL THERAPY MODALITIES; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 79958149984     PISSN: 10749357     EISSN: 19455119     Source Type: Journal    
DOI: 10.1310/tsr1803-179     Document Type: Article

References (79)

1. Broeks JG, Lankhorst GJ, Rumping K, Prevo AJ. The long-term outcome of arm function after stroke: results of a follow-up study. Disabil Rehabil. 1999;21:357-364. (Pubitemid 29410890)
2. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35:134-139. (Pubitemid 38057606)
3. Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21:247-253.
4. Twitchell TE. The restoration of motor function following hemiplegia in man. Brain. 1951;74:443-480.
5. Welmer AK, Holmqvist LW, Sommerfeld DK. Hemiplegic limb synergies in stroke patients. Am J Phys Med Rehabil. 2006;85:112-119. (Pubitemid 43162428)
6. Mirbagheri MM, Tsao C, Rymer WZ. Association of abnormal neuromuscular properties with impaired voluntary movement. Proceedings of the International Conference of Neural Control of Movement; Spain; 2004.
7. Tsao C, Mirbagheri MM. Upper limb impairments associated with spasticity in neurological disorders. J Neuro Eng Rehabil. 2007;4.
8. Voerman GE, Fleuren JF, Kallenberg LA, Rietman JS, Snoek GJ, Hermens HJ. Patient ratings of spasticity during daily activities are only marginally associated with long-term surface electromyography. J Neurol Neurosurg Psychiatry. 2009;80:175-181.
9. Wood DE, Burridge JH, van Wijck FM, et al. Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature. Disabil Rehabil. 2005;27:19-32. (Pubitemid 40124836)
10. Burridge JH, Wood DE, Hermens HJ, et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil. 2005;27:69-80. (Pubitemid 40124837)
11. Eke-Okoro ST, Gregoric M, Larsson LE. Alterations in gait resulting from deliberate changes of arm-swing amplitude and phase. Clin Biomech. 1997;12:516-521. (Pubitemid 28188153)
12. Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil. 2008;87:305-310; quiz 11, 29. (Pubitemid 351450748)
13. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206-207. (Pubitemid 17026064)
14. Brashear A, Zafonte R, Corcoran M, et al. Inter-and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upperlimb poststroke spasticity. Arch Phys Med Rehabil. 2002;83:1349-1354.
15. Fleuren JF, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry. 2009;81:46-52.
16. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6: S23-35. (Pubitemid 30029036)
17. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517-1521. (Pubitemid 19145803)
18. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16:87-101. (Pubitemid 13084857)
19. Wissel J, Muller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000;20:44-49. (Pubitemid 30628581)
20. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7:13-31.
21. Rabadi MH, Rabadi FM. Comparison of the action research arm test and the Fugl-Meyer assessment as measures of upper-extremity motor weakness after stroke. Arch Phys Med Rehabil. 2006;87:962-966. (Pubitemid 43927566)
22. Uniform Data System for Medical Rehabilitation. The FIMware User Guide and Self-Guided Training Manual, Version 5.20. Buffalo: UDSmr; 1999.
23. Williams BK, Galea MP, Winter AT. What is the functional outcome for the upper limb after stroke? Aust J Physiother. 2001;47:19-27. (Pubitemid 32192889)
24. Carr JH, Shepherd RB, Nordholm L, Lynne D. Investigation of a new motor assessment scale for stroke patients. Phys Ther. 1985;65:175-180. (Pubitemid 15140059)
25. Poole JL, Whitney SL. Motor assessment scale for stroke patients: concurrent validity and interrater reliability. Arch Phys Med Rehabil. 1988;69:195-197. (Pubitemid 18091465)
26. Stroes-Gascoyne S, Pedersen K, Haveman SA, et al. Occurrence and identification of microorganisms in compacted clay-based buffer material designed for use in a nuclear fuel waste disposal vault. Can J Microbiol. 1997;43:1133-1146. (Pubitemid 28116635)
27. Li S, Kamper DG, Rymer WZ. Effects of changing wrist positions on finger flexor hypertonia in stroke survivors. Muscle Nerve. 2006;33:183-190. (Pubitemid 43208674)
28. Kamper DG, McKenna-Cole AN, Kahn LE, Reinkensmeyer DJ. Alterations in reaching after stroke and their relation to movement direction and impairment severity. Arch Phys Med Rehabil. 2002;83:702-707. (Pubitemid 34498890)
29. Cocchiarella A, Downey J, Darling R. Evaluation of the effect of diazepam on spasticity. Arch Phys Med Rehabil. 1967;48:393-396.
30. Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841-1846. (Pubitemid 32772217)
31. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099-2109.
32. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686-689. (Pubitemid 27468690)
33. Steinberg FU, Ferguson KL. Effect of dantrolene sodium on spasticity associated with hemiplegia. J Am Geriatr Soc. 1975;23:70-73.
34. Katrak PH, Cole AM, Poulos CJ, McCauley JC. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil. 1992;73:4-9.
35. Francisco GE, Hu MM, Boake C, Ivanhoe CB. Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj. 2005;19:359-364. (Pubitemid 40796424)
36. Concalves J, Garcia-March G, Sanchez-Ledesma MJ, Onzain I, Broseta J. Management of intractable spasticity of supraspinal origin by chronic cervical intrathecal infusion of baclofen. Stereotact Funct Neurosurg. 1994;62:108-112.
37. McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59:634-640; discussion-634.
38. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996;77:35-39. (Pubitemid 26017489)
39. Koman LA, Mooney JF 3rd, Smith BP. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol. 1996;11(Suppl 1): S23-28. (Pubitemid 26408902)
40. Hisey M, Keenan M. Orthopaedic management of upper extremity dysfunction following stroke or brain injury. In: Green DP, Hotchkiss RN, Pederson WC, eds. Operative Hand Surgery. New York: Churshill Livingstone; 1998:287-324.
41. Keenan MA, Fuller DA, Whyte J, Mayer N, Esquenazi A, Fidler-Sheppard R. The influence of dynamic polyelectromyography in formulating a surgical plan in treatment of spastic elbow flexion deformity. Arch Phys Med Rehabil. 2003;84:291-296. (Pubitemid 36176772)
42. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidencebased review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707-1714. (Pubitemid 351644139)
43. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. Eur J Neurol. 2010;17(Suppl 2):1-8.
44. Shaw L, Rodgers H, Price C, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 2010;14:1-113, iii-iv.
45. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400. (Pubitemid 34851831)
46. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063-1069. (Pubitemid 38962361)
47. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol. 2002;249:76-84. (Pubitemid 34119027)
48. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000;69:217-221. (Pubitemid 30466027)
49. Kanovsky P, Bares M, Severa S, Richardson A. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol. 2009;51:436-445.
50. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004;63:1971-1973. (Pubitemid 39532408)
51. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil. 2006;87:786-792. (Pubitemid 43767710)
52. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705-709. (Pubitemid 38857904)
53. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psychiatry. 2009;80:380-385.
54. Bender L, McKenna K. Hemiplegic shoulder pain: defining the problem and its management. Disabil Rehabil. 2001;23:698-705. (Pubitemid 33076906)
55. Van Ouwenaller C, Laplace P, Chantraine A. Painful shoulder in hemiplegia. Arch Phys Med Rehabil. 1986;67:23-25.
56. Marco E, Duarte E, Vila J, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A doubleblind randomized clinical trial. J Rehabil Med. 2007;39:440-447. (Pubitemid 47082903)
57. Kong KH, Neo JJ, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil. 2007;21:28-35. (Pubitemid 46165303)
58. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke. 2008;39:126-131.
59. Marciniak C, Harvey R, Gagnon C, et al. A randomized, double-blind placebo-controlled trial of botulinum toxin type A in the treatment of hemiplegic shoulder pain and spasticity [abstract]. Arch Phys Med Rehabil. 2009;1: S100.
60. Simpson D, Mayer N. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. WE MOVE; 2002.
61. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306-1310. (Pubitemid 26159292)
62. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402-2406.
63. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:964-969. (Pubitemid 23246323)
64. Deshpande S, Gormley M, Carey J. Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study. Neurotox Res. 2006;9:115-120.
65. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002;81:355-363. (Pubitemid 34412072)
66. Mayer NH, Whyte J, Wannstedt G, Ellis CA. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Arch Phys Med Rehabil. 2008;89(5):982-987. (Pubitemid 351618387)
67. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a doubleblind controlled study. Arch Phys Med Rehabil. 2009;90:9-16 e2.
68. Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil Rehabil. 2006;28:891-897.
69. Duncan P, Studenski S, Richards L, et al. Randomized clinical trial of therapeutic exercise in subacute stroke. Stroke. 2003;34:2173-2180. (Pubitemid 37099832)
70. Wolf SL, Winstein CJ, Miller JP, et al. Retention of upper limb function in stroke survivors who have received constraint-induced movement therapy: the EXCITE randomised trial. Lancet Neurol. 2008;7:33-40. (Pubitemid 50013946)
71. Chae J, Hart R. Comparison of discomfort associated with surface and percutaneous intramuscular electrical stimulation for persons with chronic hemiplegia. Am J Phys Med Rehabil. 1998;77:516-522. (Pubitemid 29001995)
72. Levine P, Page SJ. Modified constraint-induced therapy: a promising restorative outpatient therapy. Top Stroke Rehabil. 2004;11:1-10. (Pubitemid 39658413)
73. Page SJ, Sisto S, Levine P, McGrath RE. Efficacy of modified constraint-induced movement therapy in chronic stroke: a single-blinded randomized controlled trial. Arch Phys Med Rehabil. 2004;85:14-18. (Pubitemid 38049585)
74. Hesse S, Mehrholz J, Werner C. Robot-assisted upper and lower limb rehabilitation after stroke: walking and arm/hand function. Dtsch Arztebl Int. 2008;105:330-336. (Pubitemid 351828491)
75. Levy CE, Giuffrida C, Richards L, Wu S, Davis S, Nadeau SE. Botulinum toxin a, evidencebased exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil. 2007;86:696-706. (Pubitemid 47300966)
76. Esquenazi A, Mayer N. Electrical stimulation to prolong the duration of botulinum toxin type A effects on spasticity [abstract]. Arch Phys Med Rehabil. 2007;88: E105.
77. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, doubleblind, placebo-controlled trial. Clin Rehabil. 1998;12:381-388. (Pubitemid 28464099)
78. Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined botulinum toxin type a with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair. 2010;24:34-41.
79. Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin A to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil. 2009;90:1453-1461.